POTS and HYCH as a spectrum, not separate conditions

This 2024 paper by Novak and colleagues in Frontiers in Neurology represents one of the more direct published challenges to the conventional model of POTS. The authors compared POTS patients, HYCH/OCHOS patients, and healthy controls across multiple domains including autonomic function, cerebrovascular response, and neuropathic features. What they found was that the two patient groups looked more similar than different.

Both groups showed comparable abnormalities in peripheral autonomic function. Both showed reduced cerebral blood flow during orthostatic challenge. The primary distinguishing feature was the heart rate response: POTS patients compensated with tachycardia, HYCH patients did not produce a tachycardic response of sufficient magnitude to meet diagnostic criteria. The underlying cerebral perfusion problem was present in both.

The paper makes a direct mechanistic claim. The authors state that the similarities in peripheral autonomic abnormalities affecting heart rate suggest that orthostatic tachycardia in POTS is driven by central nervous system overcompensation to the orthostatic challenge. This is a significant statement. It means the tachycardia is not a primary problem arising from a diseased heart or a failed peripheral reflex. It is the central nervous system trying to drive more blood to the brain by increasing cardiac output. Treat the tachycardia without addressing the underlying cerebral hypoperfusion and you have removed the body's compensatory mechanism while leaving the failure that triggered it completely in place.

The clinical implication is that POTS and HYCH/OCHOS should be thought of as points on a spectrum of orthostatic cerebral hypoperfusion, differentiated by compensatory response rather than by fundamentally different underlying pathology. Testing that only identifies one end of this spectrum, the tachycardic end, will miss a large portion of patients who are experiencing the same core problem through a different compensatory pathway.